Mucosal melanoma: from molecular landscape to current treatment strategies

Jane Mattei, Eduardo N. Trindade, Marcio F. Chedid

Research output: Contribution to journalReview articlepeer-review


Mucosal melanoma (MM) is an aggressive tumor originating from melanocytes located in the respiratory, gastrointestinal, and urogenital tract with clinical and pathologic characteristics distinct from cutaneous melanoma. In addition, MMs have a unique biology that contributes to delayed diagnosis and, therefore an adverse prognosis. The factors all contribute to a treatment paradigm unique from its more studied cutaneous brethren. Due to the rarity of this disease, well-established protocols for the treatment of this pathology have yet to be established. The use of immune checkpoint inhibitors patterned after cutaneous melanoma has become the de facto primary therapeutic approach; however, cytotoxic strategies and pathway-targeted therapies have a defined role in treatment. Judicious use of these approaches can give rise to durable unmaintained disease responses.

Original languageEnglish (US)
Pages (from-to)447-453
Number of pages7
JournalMelanoma Research
Issue number6
StatePublished - Dec 1 2023
Externally publishedYes


  • PD-1
  • biochemotherapy
  • checkpoint inhibitors
  • imatinib
  • immunotherapy
  • mucosal melanoma
  • nivolumab
  • pembrolizumab
  • target therapy
  • treatment

ASJC Scopus subject areas

  • Dermatology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Mucosal melanoma: from molecular landscape to current treatment strategies'. Together they form a unique fingerprint.

Cite this